ADRB2 and Alzheimer disease: However, several clinical trials evaluated the therapeutic potential of adrenergic-agents against AD, including α2C AR antagonist ORM-12741 (https://clinicaltrials.gov/ct2/show/NCT01324518) and β2 AR agonist formoterol (https://clinicaltrials.gov/ct2/show/NCT02500784).